CHAPEL HILL, N.C.--(BUSINESS WIRE)--July 15, 2008--POZEN Inc.
(NASDAQ: POZN), announced today that it will release second quarter
2008 results on July 29, 2008, before the market opens.
The announcement will be followed by a live webcast at 10:00 a.m.
Eastern Time with a discussion by POZEN management of the earnings and
business results. The webcast can be accessed on POZEN's website at
www.pozen.com and will be archived and available for replay. The
second quarter 2008 earnings release will be accessible in the News
section of POZEN's website.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for Treximet(TM), which was recently
approved by the United States Food and Drug Administration for the
acute treatment of migraine attacks; and with AstraZeneca for
proprietary fixed dose combinations of naproxen with the proton pump
inhibitor esomeprazole magnesium in a single tablet for conditions
such as osteoarthritis and rheumatoid arthritis in patients who are at
risk for developing NSAID-associated gastric ulcers. The company's
common stock is traded on The Nasdaq Stock Market under the symbol
"POZN". For detailed company information, including copies of this and
other press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.
Chief Financial Officer
Director, Investor Relations
SOURCE: POZEN Inc.